Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Diagnostic biomarkers of prostate cancer.

Häggarth L, Hägglöf C, Jaraj SJ, Wester K, Pontén F, Ostman A, Egevad L.

Scand J Urol Nephrol. 2011 Feb;45(1):60-7. doi: 10.3109/00365599.2010.526141. Epub 2010 Nov 1.

PMID:
21034352
2.

Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).

Jiang Z, Woda BA, Wu CL, Yang XJ.

Am J Clin Pathol. 2004 Aug;122(2):275-89. Review.

3.

Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.

Jiang Z, Woda BA.

Adv Anat Pathol. 2004 Nov;11(6):316-21. Review.

PMID:
15505533
5.
6.

Immunohistochemistry in diagnostic surgical pathology of the prostate.

Hameed O, Humphrey PA.

Semin Diagn Pathol. 2005 Feb;22(1):88-104. Review.

PMID:
16512601
7.

[Immunohistochemical algorithms in prostate diagnostics: what's new?].

Kristiansen G.

Pathologe. 2009 Dec;30 Suppl 2:146-53. doi: 10.1007/s00292-009-1230-4. Review. German.

PMID:
19795124
8.

Human prostate cancer precursors and pathobiology.

De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG.

Urology. 2003 Nov;62(5 Suppl 1):55-62. Review.

PMID:
14607218
9.

Immunohistochemical pitfalls in prostate pathology.

Brimo F, Epstein JI.

Hum Pathol. 2012 Mar;43(3):313-24. doi: 10.1016/j.humpath.2011.11.005. Review.

PMID:
22325142
10.
12.

Other biomarkers for detecting prostate cancer.

Nogueira L, Corradi R, Eastham JA.

BJU Int. 2010 Jan;105(2):166-9. doi: 10.1111/j.1464-410X.2009.09088.x. Epub 2009 Nov 20. Review.

13.

Applicability of biomarkers in the early diagnosis of prostate cancer.

Hessels D, Verhaegh GW, Schalken JA, Witjes JA.

Expert Rev Mol Diagn. 2004 Jul;4(4):513-26. Review.

PMID:
15225099
14.

Advances in biomarkers for the early diagnosis of prostate cancer.

Cao DL, Yao XD.

Chin J Cancer. 2010 Feb;29(2):229-33. Review.

15.

Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics.

Wu A, Kunju LP.

Arch Pathol Lab Med. 2013 Sep;137(9):1179-84. doi: 10.5858/arpa.2013-0254-CR. Review.

PMID:
23991727
16.

Phytanic acid, AMACR and prostate cancer risk.

Thornburg T, Turner AR, Chen YQ, Vitolins M, Chang B, Xu J.

Future Oncol. 2006 Apr;2(2):213-23. Review.

PMID:
16563090
17.

Biopsy sampling and histopathological markers for diagnosis of prostate cancer.

Rodrigues Â, Freitas R, Nogueira-Silva P, Jerónimo C, Henrique R.

Expert Rev Anticancer Ther. 2014 Nov;14(11):1323-36. doi: 10.1586/14737140.2014.965688. Epub 2014 Oct 2. Review.

PMID:
25278357
18.

Biomarker research in prostate cancer--towards utility, not futility.

Oon SF, Pennington SR, Fitzpatrick JM, Watson RW.

Nat Rev Urol. 2011 Mar;8(3):131-8. doi: 10.1038/nrurol.2011.11. Review.

PMID:
21394176
19.

A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.

Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD.

Adv Anat Pathol. 2013 Jan;20(1):39-44. doi: 10.1097/PAP.0b013e31827b665b. Review.

20.

Diagnostic and prognostic molecular biomarkers for prostate cancer.

Kristiansen G.

Histopathology. 2012 Jan;60(1):125-41. doi: 10.1111/j.1365-2559.2011.04083.x. Review.

PMID:
22212082
Items per page

Supplemental Content

Write to the Help Desk